We conclude that small-molecule inhibitors such as PBrP that target vesicle trafficking and inhibit TGF-β signalling could be developed into a broad-spectrum therapeutic agent to cure cancer and fibrosis diseases. The gene discussed is TGFB1; the disease is cancer.